INIS
antibodies
100%
performance
65%
sensitivity
48%
detection
44%
pcr
42%
coronaviruses
41%
validation
40%
elisa
36%
messenger-rna
36%
patients
34%
covid-19
34%
antigens
30%
gsd
30%
vaccines
30%
laboratories
30%
comparative evaluations
29%
kinetics
29%
evaluation
23%
specificity
22%
chemiluminescence
22%
doses
21%
data
21%
testing
21%
symptoms
19%
workers
18%
escherichia coli
18%
assessments
18%
mutations
18%
surveillance
18%
pathogens
18%
immunoglobulins
18%
screening
18%
hospitals
18%
implementation
18%
management
15%
manufacturers
15%
genes
13%
immunoassay
12%
diseases
12%
viruses
10%
investigations
9%
virulence
9%
injection
9%
cost
9%
agglutination
9%
cleaning
9%
reactivity
9%
hydrogen 7
9%
disinfection
9%
children
9%
Keyphrases
MRNA-1273
18%
COVID Vaccine
18%
Third Dose
18%
Immunoglobulin M Antibody
18%
Analytical Validation
18%
Clinical Validation
18%
Dual Recognition
18%
Antibody Kinetics
18%
IgM Antibody
18%
SARS-CoV-2 Detection
18%
Symptom Onset
18%
Extraction-free
18%
Nursery
18%
RT-polymerase Chain Reaction
18%
SARS-CoV-2 IgG Antibody
18%
Efficacy Comparison
18%
Load Impact
18%
SARS-CoV-2 Variants of Concern
18%
Chemiluminescence Detection
18%
Clinical Performance
18%
SARS-CoV-2 Antibodies
18%
Molecular Techniques
12%
SARS-CoV-2 Assay
12%
Aptima
9%
SARS-CoV-2 Infection
9%
Non-hospitalized
9%
Antibody Signature
9%
Onychomycosis
9%
N501Y
9%
L452R mutation
9%
L452R
9%
Mutation Detection
9%
Local Epidemiology
9%
Immunoglobulin M
6%
Total Antibody
6%
Limited Environments
6%
Interim Analysis
6%
Severe COVID-19 Disease
6%
Anti-S Antibodies
6%
Medical Questionnaires
6%
Symptomatic Cases
6%
Nimbus
6%
Conventional Analysis
6%
S Gene
6%
AggR
6%
COVID-19 Patients
6%
Thermal Shock
6%
Targeted Gene
6%
SARS-CoV-2 Test
6%
N Gene
6%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
61%
Immunoglobulin G Antibody
39%
Immunoglobulin M Antibody
36%
Polymerase Chain Reaction
21%
Immunogenicity
18%
ELISA
18%
Humoral Immunity
18%
Enteroaggregative Escherichia Coli
18%
Neutralizing Antibody
18%
Cross-Reactivity
14%
Respiratory Virus
13%
COVID-19
13%
Binding Antibody
12%
Immunoassay
10%
Aegle
9%
Monospecific Antibody
9%
Immunoglobulin M
9%
Wild Type
6%
Immunology
6%
Antibiotic Sensitivity
6%
Omicron Coronavirus Variant
6%
Turnaround Time
6%